References

Multiple myeloma

10.1038/nrdp.2017.46 · 2017 · External reference

Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies

10.1038/s41408-021-00480-w · 2021 · External reference

Long-term follow-up of monoclonal gammopathy of undetermined significance

10.1056/nejmoa1709974 · 2018 · External reference

Familial risks and temporal incidence trends of multiple myeloma

10.1016/j.ejca.2005.11.033 · 2006 · External reference

Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden

10.1002/ijc.24514 · 2009 · External reference

Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study

1992 · External reference

Familial myeloma

10.1056/nejmoa0708704 · 2008 · External reference

Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden

10.1182/blood-2008-12-191676 · 2009 · External reference

Genetic predisposition for multiple myeloma

10.1038/s41375-019-0703-6 · 2020 · External reference

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma

10.1038/ncomms12050 · 2016 · External reference

Deciphering the genetics and mechanisms of predisposition to multiple myeloma

10.1038/s41467-024-50932-7 · 2024 · External reference

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

10.1038/s41467-018-04989-w · 2018 · External reference

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

10.1038/s41375-020-0718-z · 2020 · External reference

Randomized trial of lenalidomide versus observation in smoldering multiple myeloma

10.1200/jco.19.01740 · 2020 · External reference

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

10.1056/nejmoa1300439 · 2013 · External reference

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

10.1016/s1470-2045(14)70442-5 · 2014 · External reference

Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management

10.1002/ajh.24557 · 2017 · External reference

Risk of multiple myeloma and other malignancies among first- and second-degree relatives of patients with multiple myeloma: a population-based study

10.1111/ejh.13757 · 2022 · External reference

The PROMISE study: a nationwide project for predicting the progression of developing myeloma in a high-risk screened population

10.1016/j.clml.2019.09.509 · 2019 · External reference

Daratumumab or active monitoring for high-risk smoldering multiple myeloma

10.1056/nejmoa2409029 · 2025 · External reference

Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significance risk stratification

10.1038/s41408-025-01337-2 · 2025 · External reference

Development of a multivariable model to predict the need for bone marrow sampling in persons with monoclonal gammopathy of undetermined significance: a cohort study nested in a clinical trial

10.7326/m23-2540 · 2024 · External reference

Prevalence of smoldering multiple myeloma based on nationwide screening

10.1038/s41591-022-02183-6 · 2023 · External reference

Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States

10.1182/blood-2005-08-3449 · 2006 · External reference

Racial disparities in incidence and outcome in multiple myeloma: a population-based study

10.1182/blood-2010-07-298760 · 2010 · External reference